Performance Meeting Overview - The company held a performance meeting on December 3, 2025, to discuss its third-quarter results, attended by key executives and independent directors [1] - The meeting addressed investor concerns regarding stock price decline and sales performance of the flagship product, Xinhuosu [1][2] Sales Performance and Revenue Impact - Xinhuosu's sales decreased in the third quarter due to sales fluctuations, impacting overall revenue [2][3] - The company plans to stabilize Xinhuosu's sales while increasing sales of other products like Nuo, Jin, and Shi to enhance overall performance [3] Future Growth Strategies - The main growth drivers identified for the fourth quarter and beyond include stabilizing Xinhuosu sales and enhancing sales through new media marketing and cinema distribution for products like Nuo and Jinluohan [4] - The company aims to achieve growth through both internal and external strategies, focusing on R&D investment, mergers, and innovative product development [5][6] Investment and Risk Management - The company is closely monitoring industry policies and market conditions to manage investment risks effectively [3] - Future investments will focus on high-tech biopharmaceuticals, particularly cardiovascular products, while remaining open to high-revenue oncology drugs [6]
西藏诺迪康药业股份有限公司关于2025年第三季度业绩说明会召开情况的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-12-04 08:43